Details of the Drug
General Information of Drug (ID: DMATB8H)
| Drug Name | 
                     2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide 
                 | 
            ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | 
                                         
                        CHEMBL23285; 2,2-dimethyl-N-(4-sulfamoylphenyl)propanamide; 103826-87-5; AC1MBHEI; Oprea1_396828; p-pivaloylaminobenzenesulfonamide; Propanamide, N-[4-(aminosulfonyl)phenyl]-2,2-dimethyl-; N-(4-Sulfamoylphenyl)Pivalamide; SCHEMBL10603454; ZINC73524; BDBM16649; aromatic sulfonamide compound 14; CCG-916; KGBTVIQRHXYTRQ-UHFFFAOYSA-N; 4-Pivaloylamido-benzenesulfonamide; MolPort-002-912-681; AKOS003441276; MCULE-2674794031; BRD-K77020128-001-01-6
                        
                     
                                     | 
            ||||||||||||||||||||||
| Indication | 
                                                            
  | 
            ||||||||||||||||||||||
| Drug Type | 
                     Small molecular drug 
                 | 
            ||||||||||||||||||||||
| Structure | 
                    ![]()  | 
            ||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 256.32 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.4 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
| Chemical Identifiers | 
                        
  | 
                ||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT)  | 
                
                    
  | 
            ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||||||||
                    
  | 
            ||||||||||||||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||||||||


